Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SEXSWX:EVT 58 EV-to-OCF is 32.34 as of Aug. 13, 2026, which is 3% above its 10-year median of 31.49. GuruFocus rates XSWX:EVT with a GF Score™ of 58/100 and a GF Value™ of CHF8.56. The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Evotec SE ranks worse than 80.42% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Evotec SE's Enterprise Value is CHF569.1 Mil.
Evotec SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF17.6 Mil. Therefore, Evotec SE's EV-to-OCF for today is 32.34.
The historical rank and industry rank for Evotec SE's EV-to-OCF or its related term are showing as below:
XSWX:EVT'
s EV-to-OCF Range Over the Past 10 Years
Min: -260.68 Med: 31.49 Max: 785.36
Current: 32.48
During the past 13 years, the highest EV-to-OCF of Evotec SE was 785.36. The lowest was -260.68. And the median was 31.49.
XSWX:EVT's EV-to-OCF is ranked worse than 80.42% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.145
vs XSWX:EVT: 32.48
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Evotec SE's share price for today is CHF4.63.
Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.993.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Evotec SE EV-to-OCF Related Terms
Evotec SE EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Evotec SE's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Evotec SE's EV-to-OCF falls into.
Evotec SE's current Enterprise Value is CHF569.1 Mil.
Evotec SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF17.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (XSWX:EVT) has a EV-to-OCF of 32.34 as of Aug. 13, 2026. This is near median its historical median of 31.49. According to the industry distribution chart, Evotec SE ranks #809 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 80.4%.
Is Evotec SE's EV-to-OCF too high?
Evotec SE's current EV-to-OCF of 32.34 is near median its 10-year median of 31.49. The Drug Manufacturers industry median EV-to-OCF is 11.15. Evotec SE's value of 32.34 is 190.2% above this industry median. Based on the distribution chart, Evotec SE ranks #809 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #809 out of 1006 companies for EV-to-OCF. This places Evotec SE in the lower half of its industry. The industry median EV-to-OCF is 11.15. Evotec SE's value of 32.34 is 190.2% above this benchmark. While the company's 10-year median is 31.49 vs. the industry median of 11.15, Evotec SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.15, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current EV-to-OCF of 32.34 is 190.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current EV-to-OCF is 32.34, which is near median its own 10-year median of 31.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (XSWX:EVT) has a current EV-to-OCF of 32.34. The stock's GF Value™ is CHF8.56, compared to a current price of CHF4.63 — trading 45.9% below its estimated fair value. The current EV-to-OCF is 32.34, which is near median its 10-year median of 31.49 and 190.2% above the Drug Manufacturers industry median of 11.15. Evotec SE's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current EV-to-OCF is 32.34 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.63 is trading 45.9% below its estimated GF Value™ of CHF8.56.
Key valuation signals for XSWX:EVT:
EV-to-OCF: 32.34 (near median its 10-year median of 31.49)
GF Value™: CHF8.56 vs. price of CHF4.63 (45.9% below fair value)
Industry Position: 190.2% above the Drug Manufacturers median (#809 of 1006)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
58GF Score
Get the complete analysis for XSWX:EVT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
